Abstract
The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents. However, there is emerging evidence that HDAC inhibitors could have utility in the treatment of chronic immune and inflammatory disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, airway hyperresponsiveness and organ transplant rejection. Here we discuss the merits of various, structurally-distinct HDAC inhibitors as potential anti-inflammatory therapeutics and provide examples of the novel medicinal chemistry approaches being undertaken to realize HDAC as a druggable target in this clinical setting.
Keywords: Histone deacetylases, inhibitors, inflammation, immune disease, FK228, deacetylases, multiple sclerosis, rheumatoid arthritis, psoriasis, histones, nuclear proteins, T-cell lymphoma, (FDA), GM-CSF, TNFα, TGFβ, (MMPs), iNOS, IL-1β, IFN-, (Tregs), Cyclosporin-A, IL-2, (ZEB), (CtBP), CD4+ T, FR276457, (GVHD), (T-cell depletion), phosphorylation, (IBD), (SLE), CD28, RASFs, KBH-A42, Trichostatin-A, Vorinostat, chemokines, CTCL
Current Drug Targets
Title: Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Volume: 11 Issue: 11
Author(s): Stephen J. Shuttleworth, Sarah G. Bailey and Paul A. Townsend
Affiliation:
Keywords: Histone deacetylases, inhibitors, inflammation, immune disease, FK228, deacetylases, multiple sclerosis, rheumatoid arthritis, psoriasis, histones, nuclear proteins, T-cell lymphoma, (FDA), GM-CSF, TNFα, TGFβ, (MMPs), iNOS, IL-1β, IFN-, (Tregs), Cyclosporin-A, IL-2, (ZEB), (CtBP), CD4+ T, FR276457, (GVHD), (T-cell depletion), phosphorylation, (IBD), (SLE), CD28, RASFs, KBH-A42, Trichostatin-A, Vorinostat, chemokines, CTCL
Abstract: The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents. However, there is emerging evidence that HDAC inhibitors could have utility in the treatment of chronic immune and inflammatory disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, airway hyperresponsiveness and organ transplant rejection. Here we discuss the merits of various, structurally-distinct HDAC inhibitors as potential anti-inflammatory therapeutics and provide examples of the novel medicinal chemistry approaches being undertaken to realize HDAC as a druggable target in this clinical setting.
Export Options
About this article
Cite this article as:
J. Shuttleworth Stephen, G. Bailey Sarah and A. Townsend Paul, Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases, Current Drug Targets 2010; 11 (11) . https://dx.doi.org/10.2174/1389450111009011430
DOI https://dx.doi.org/10.2174/1389450111009011430 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alzheimers Disease: Targets For Drug Development
Mini-Reviews in Medicinal Chemistry Omega-3 Fatty Acids Supplementation in Psychiatric Disorders: A Systematic Review
Current Psychopharmacology Peripheral Mononuclear Cell Rejuvenation for Senescence Surveillance in Alzheimer Disease
Current Pharmaceutical Design Impact of HLA Haplotype on the Response to Antipsychotic Treatment of Schizophrenia
Current Pharmacogenomics Applications of Umbilical Cord Derived Mesenchymal Stem Cells in Autoimmune and Immunological Disorders: From Literature to Clinical Practice
Current Stem Cell Research & Therapy Leptin: The Prototypic Adipocytokine and its Role in NAFLD
Current Pharmaceutical Design Prevalence of Anti-nuclear and Anti-phospholipid Antibodies in an Egyptian Cohort with Schizophrenia: A Case-control Study
Current Rheumatology Reviews Analysis of Nucleic Acids and Proteins in Capillary Electrophoresis and Microchip Capillary Electrophoresis Using Polymers as Additives of the Background Electrolytes
Current Analytical Chemistry Drugs, Trials and Pathogenesis: Will Connecting these Help us Understand SLE?
Current Rheumatology Reviews Mechanistic Systems Biology of Inflammatory Gene Expression in Airway Smooth Muscle as Tool for Asthma Drug Development
Current Drug Discovery Technologies Two Different Functions of Doxycycline Which is Both An Antimicrobial Agent and An Immune Modulator
Anti-Infective Agents in Medicinal Chemistry Cholinergic Targets in Lung Cancer
Current Pharmaceutical Design Quantitative Structure-Activity Relationships for Commercially Available Inhibitors of COX-2
Medicinal Chemistry Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Snake Venom Metalloproteinases: Structure, Mechanism and Induced Diseases
Current Chemical Biology Glyco-Engineering of Human IgG-Fc to Modulate Biologic Activities
Current Pharmaceutical Biotechnology Hepatocyte Growth Factor in Normal and Diseased Bone and Joint Tissues
Current Rheumatology Reviews Therapeutic Benefits of Regulating Inflammation in Autoimmunity
Inflammation & Allergy - Drug Targets (Discontinued) Lipid Nanoparticles and their Application in Nanomedicine
Current Pharmaceutical Biotechnology The Contribution of Adipose Tissue and Adipokines to Inflammation in Joint Diseases
Current Medicinal Chemistry